EMA Invites Comments on New Guidance for Vaccine Development - - BioPharm International

ADVERTISEMENT

EMA Invites Comments on New Guidance for Vaccine Development


The European Medicines Agency (EMA) has released the second module of a new guideline on influenza vaccines for a six-month public consultation. The guidance covers the non-clinical and clinical requirements for the development of new influenza vaccines and aims to facilitate the prompt assessment of new vaccines. It follows the publication of a module on the quality requirements.

The new modular guideline is intended to cover and update in one single, consolidated document the existing guidance on regulatory, quality, non-clinical and clinical aspects of the development of all types of influenza vaccines, in all epidemiological situations, i.e., seasonal, pandemic and pre-pandemic.

It has been developed based on the experience gained from many years of seasonal vaccination campaigns, the 2009/2010 influenza A (H1N1) pandemic, requests for scientific advice received from vaccine developers and applications for marketing authorization.

The guidance provided applies to vaccines for which ample regulatory experience has been gained, as well as to some novel types of vaccines based on established surface antigens.
The most notable changes introduced by the non-clinical and clinical module of the guideline include: new terminology for pandemic vaccines to replace the term pandemic mock up vaccine with ‘pandemic preparedness vaccines’ and the term pre-pandemic vaccines with ‘zoonotic influenza vaccines’; revision of criteria for the assessment of immunogenicity in favor of a broader evaluation of immune responses rather than the use of seroprotection rate and hemagglutination inhibition as the main tests for evaluation; and an introduction of effectiveness studies for seasonal influenza vaccines as requirements in the post-authorization phase.

The guidance on enhanced safety surveillance for seasonal influenza vaccines, which was adopted as a stand-alone document in April 2014, will be annexed to this module following its finalization.

Comments are invited until 31 January 2015 and should be sent to vwp@ema.europa.eu using the form provided. 

Source: EMA

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here